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The Origin of Urinary Stones
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Urinary stone disease has historically been viewed as a disorder of mineral metabolism 
leading to precipitation of minerals out of the urine. Therefore, the medical manage-
ment of urinary stones has focused on improving the urinary milieu. A growing body of 
evidence suggests that both cardiovascular risk factors and cardiovascular disease it-
self are associated with the development of urinary stones. Although disorders of min-
eral metabolism and cardiovascular diseases are both systemic conditions, patients 
frequently present with asymmetric renal calculus disease, suggesting that as yet un-
characterized local mechanisms must contribute to the formation of renal calculi. In this 
review, we examine the links between cardiovascular disease and nephrolithiasis, and 
discuss the evidence for potential local factors that contribute to stone disease.
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1. Introduction
In the 5th century BC, Hippocrates, or one of his stu-
dents, wrote in the Hippocratic Oath, “I will not use the 
knife, not even on sufferers from stone, but will withdraw 
in favor of such men as are engaged in this work… .”1 It is 
notable that urinary stone disease is the only medical 
condition specifically mentioned by name in the ancient 
Hippocratic Oath, indicating the enormity of the problem. 
Currently, even in developed countries, urinary stone dis-
ease represents a very large burden upon the health and 
welfare of the general population. For example, in the 
United States, the 16,115 patient NHANES III epidemio-
logic study from the period 1988–1994 has established 
the lifetime prevalence of urinary stone disease to be ap-
proximately 5.2%.2 Even more troublesome is that this 
appears to represent an increase in urinary stone disease 
compared with the previous NHANES II study from 1976 
to 1980, which recorded a lifetime prevalence of only 3.2%.
Since 1993, the United States Nationwide Inpatient 
Sample (NIS) has recorded a gradual decline in the num-
ber of inpatient discharges for upper urinary tract stone 
disease (Figure 1). Although this may be due in part to 
improved medical management of urinary stone disease, 
it may also reflect the trend in the United States toward 
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Figure 1 Number of inpatient discharges for upper urinary 
tract stone disease from 1993 to 2007. These data do not include 
information on outpatient procedures. Data were obtained from 
the US Nationwide Inpatient Sample.3
surgical treatment of urinary stone disease on an out-
patient basis. Nevertheless, in 2007, the NIS recorded 
155,860 urinary stone inpatient discharges. At an esti-
mated true cost of US$6,128 per inpatient discharge, the 
total cost of these inpatient discharges is US$955,192,450.3 
Because a lot of urinary stone disease treatment also occurs 
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in the outpatient setting not captured by the NIS, the 
total cost for treatment of urinary stone disease in the 
United States is likely to be several orders of magnitude 
larger. Outside of developed countries, urinary stone dis-
ease is an even greater problem. In the developing world, 
urinary stone disease accounts for up to 50% of urologic 
procedures.4 Furthermore, while urinary stone disease is 
the primary contributing factor for end-stage renal dis-
ease in only 1% of patients in developed countries, it ac-
counts for up to 20% of patients on dialysis in countries 
such as Indonesia and Thailand. Urinary stone disease is, 
therefore, a global health priority.
Urinary stone disease has historically been viewed as 
a disorder of mineral metabolism leading to precipitation 
of minerals out of the urine. Therefore, the medical man-
agement of urinary stones has focused on improving the 
urinary mineral milieu. Although significant successes have 
been achieved through techniques such as increased fluid 
intake, alkali loading, inhibition of calcium excretion, and the 
use of binding agents, these approaches appear to simply 
manipulate the urinary environment rather than prevent 
the potential true precursors of urinary stones. One issue is 
that 20–30% of stone-forming patients do not demonstrate 
any metabolic abnormality in 24-hour urine studies.5 
Additional contributing factors must, therefore, be involved 
in the development of renal stones. In this review, we dis-
cuss the evidence for potential non-mineral metabolism 
factors in the development of urinary calculi.
2.  Cardiovascular Risk Factors and Urinary 
Stone Disease
A growing body of evidence suggests that there are links 
between various cardiovascular risk factors and the de-
velopment of urinary stones. Using the 51,529-patient 
Health Professionals Follow-up Study (HPFS) database, 
Taylor et al.6 found that obese males with a body mass 
index (BMI) of 30 or greater had an increased risk for the 
development of urinary stones compared with non-obese 
men with an odds ratio (OR) of 1.33 (95% confidence in-
terval, CI, 1.08–1.63). The risk was even higher in obese 
women; the ORs for the development of urinary stones 
were 1.90 (95% CI, 1.61–2.25) in the first Nurses’ Health 
Study (NHS I) and 2.09 (95% CI, 1.77–2.48) in the second 
Nurses’ Health Study (NHS II).
Significant correlations have also been found between 
hypertension and the development of urinary stones in 
multiple studies. ORs for the development of urinary 
stones in patients with hypertension have ranged from 
1.79 to 5.50 in relatively small studies that included up 
to 688 patients.7 In larger epidemiologic studies, how-
ever, the relationships are less pronounced. In the HPFS, 
Madore et al.8 found that there was no increased risk of 
urinary stone disease in men with hypertension and that 
the OR was not significant at 0.99 (95% CI, 0.82–1.21). 
Similarly, in the NHS II, the OR for the development of 
urinary stones in women with hypertension compared with 
women without hypertension was 1.01 (95% CI, 0.85–
1.20).9 Interestingly, however, there are statistically signifi-
cant increased risks for the development of hypertension 
in patients who have urinary stone disease with ORs 
of 1.29 (95% CI, 1.12–1.41) for men and 1.24 (95% CI, 
1.13–1.37) for women.8,9
In addition to obesity and hypertension, diabetes mel-
litus has also been associated with an increased risk of 
urinary stone disease. In the HPFS, diabetic men were 
found to be at increased risk for the development of uri-
nary stone disease with a relative risk (RR) for stones 
of 1.21 (95% CI, 1.03–1.42) when compared with non-
diabetics.10 Similar to diabetic men, diabetic women have 
also been found to have an increased risk for urinary 
stone disease. In the NHS I and NHS II, the RRs for the 
development of urinary stones in diabetic women com-
pared with non-diabetics were 1.55 (95% CI, 1.20–1.99) 
and 1.84 (95% CI, 1.41–2.41), respectively.10
3.  Metabolic Syndrome and Urinary Stone 
Disease
The prevalence of increased urinary stone disease is 
matched by an increased prevalence of metabolic syn-
drome. By definition, metabolic syndrome exists when at 
least three of the following five atherogenic risk factors 
are present: abdominal obesity, hypertension, diabetes 
mellitus, elevated triglycerides, and decreased high-
density lipoprotein. In the NHANES III 1988–1994 study, 
the age-adjusted prevalence of metabolic syndrome was 
24.1%. In the NHANES 1999–2000 study, the age-adjusted 
prevalence of metabolic syndrome had risen to 27.0% 
(p = 0.043).11 Based upon data from the NHANES III data-
base, the rate of self-reported urinary stone disease was 
found to increase as the number of metabolic syndrome 
traits also increased.12 With no metabolic syndrome traits, 
the prevalence of urinary stone disease is 3%. However, 
with three traits, the prevalence of urinary stone dis-
ease increases to 7.5%, and with all five traits, the preva-
lence of urinary stone disease increases to 9.8%. Indeed, 
the age, sex and race-adjusted odds ratio for urinary 
stone disease in patients with all five metabolic syndrome 
traits is 1.93 (95% CI, 1.08–3.43) compared with patients 
with no traits. These findings strongly suggest that uri-
nary stone disease is indeed associated with cardiovas-
cular risk factors.
4.  Cardiovascular Disease and Urinary Stone 
Disease
Evidence suggests that cardiovascular risk factors are 
closely correlated with the occurrence of urinary stone 
disease. Recent analyses of the HPFS and the Study of 
Osteoporotic Fractures suggest that cardiovascular disease 
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itself is also correlated with urinary stone disease. Spe-
cifically, in the HPFS, men with urinary stone disease have 
an increased risk of coronary artery disease, myocardial 
infarction, and coronary artery bypass grafting compared 
with men without stone disease with RRs of 1.15 (95% 
CI, 1.06–1.26), 1.16 (95% CI, 1.02–1.33), and 1.16 (95% 
CI, 1.05–1.28), respectively (M.L. Stoller and colleagues, 
unpublished data, 2009). Among the 9480 women of 
the Study of Osteoporotic Fractures, women with urinary 
stone disease also have an increased risk of angina, my-
ocardial infarction, and congestive heart failure with RRs 
of 1.61 (95% CI, 1.18–2.23), 1.78 (95% CI, 1.21–2.62), 
and 2.23 (95% CI, 1.30–3.84), respectively (M.L.S. et al., 
unpublished data, 2009).
5.  Cardiovascular Risk Factors and Urinary 
Metabolic Stone Risk Parameters
Based on evidence linking both cardiovascular risk factors 
and cardiovascular disease itself to urinary stone disease, 
several groups of investigators have sought to character-
ize the potential metabolic derangements associated with 
individual cardiovascular risk factors. Ekeruo et al.13 per-
formed a case-control study comparing the 24-hour urine 
values of 83 obese patients whose BMIs were 30 or greater 
with sex-matched non-obese controls. When compared 
with non-obese patients, obese patients were found to 
have statistically significant less favorable 24-hour urinary 
excretion of calcium, uric acid, and oxalate. Urinary pH 
was also significantly more acidic in obese patients com-
pared with non-obese patients. However, total 24-hour 
urine volume and urinary citrate excretion were signifi-
cantly more favorable in obese patients compared with 
non-obese patients.
Borghi et al.14 performed a case-control study com-
paring the 24-hour urine values of 132 non-stone forming 
patients with stable essential hypertension with age- and 
sex-matched normotensive controls. When adjusted for 
BMI, hypertensive patients had an increased 24-hour cal-
cium excretion, which was statistically insignificant, but 
a significantly increased 24-hour oxalate excretion. Using 
data from the HPFS, NHS I and NHS II, Taylor et al.15 
found that there was no trend toward an increased prev-
alence of hypertension in patients with increased calcium 
excretion. However, there was an increased prevalence 
of hypertension in patients with decreased citrate excre-
tion. From these findings, the authors theorized that hy-
pertension leads to metabolic acidosis, which may result 
in increased reabsorption of citrate from the proximal 
convoluted tubule.
With regard to urinary metabolic stone risk in diabe-
tes mellitus, Pak et al.16 compared the 24-hour urine val-
ues of type 2 diabetics with uric acid and calcium stones 
with those of non-diabetics with gouty diathesis and hy-
peruricosuric calcium nephrolithiasis. In this study, most 
urine parameters were more favorable in non-diabetics 
compared with diabetics. Citrate, however, tended to be 
more favorable in diabetic patients compared with non-
diabetic patients. Although urine pH was not signifi-
cantly different between type 2 diabetics with uric acid 
stones and non-diabetics with gouty diathesis, it was 
significantly more acidic in type 2 diabetics with calcium 
stones compared with hyperuricosuric non-diabetics with 
calcium stones.
6.  Asymmetry of Urinary Stone Disease
Mineral metabolism disorders and cardiovascular disease 
are systemic diseases. As such, both kidneys should the-
oretically be equally affected, and urinary stone disease 
should, therefore, be bilateral and symmetric. Anecdotal 
evidence, however, suggests that patients frequently 
present with asymmetric urinary stone disease (Figure 2). 
To better address this issue, we examined the incidence 
of nephrocalcinosis, which is thought to be the precur-
sor lesion to free-floating nephrolithiasis, in patients with 
the systemic disorder of severe hypocitraturia defined as 
24-hour urinary citrate excretion less than 50 mg (M.L.S. 
et al., submitted data, 2009). Of the 44 patients with 
severe hypocitraturia in the University of California San 
Francisco metabolic stone database between 2001 and 
2008, 22 patients had nephrocalcinosis. While equal num-
bers of right and left kidneys were affected, nine patients 
(41%) had only unilateral nephrocalcinosis. Of the 35 af-
fected kidneys, 14 kidneys (40%) had nephrocalcinosis in 
only one segment, 13 kidneys (37%) had nephrocalcino-
sis in two segments, and only eight kidneys (23%) had 
nephrocalcinosis involving all three segments. These find-
ings suggest that nephrocalcinosis is asymmetric both be-
tween kidneys and within kidneys despite the systemic 
nature of the mineral metabolism disorder.
In addition to the evidence suggesting that nephrocal-
cinosis is frequently asymmetric, it also has been dem-
onstrated that the laterality of urinary stone disease can 
be correlated with sleep posture. Out of 110 consecutive 
Figure 2 Plain abdominal radiograph demonstrating asymmet-
ric renal calculi. This patient had no history of nephrolithiasis in 
the left kidney.
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patients at University of California San Francisco with uni-
lateral stone disease on imaging, 82% of patients who 
slept left side down formed their stones on the left side, 
while 70% of patients who slept right side down formed 
their stones on the right side.17 Overall, 76% of patients 
formed their stones in the kidney, which was dependent 
on the sleeping position. Although it is possible that pa-
tients who sleep on a particular side may do so because 
of enhanced comfort due to pre-existing unilateral stone 
disease, it appears that there is a strong correlation be-
tween stone laterality and sleeping posture.
One of the primary differences between the kidneys 
when a patient is in the lateral decubitus position is due to 
perfusion. In a study of 10 non-stone-forming patients who 
underwent mercaptoacetyltriglycine renal scans in the su-
pine, left lateral decubitus and right lateral decubitus po-
sitions, we demonstrated that perfusion to the dependent 
kidney was 61–63%, while perfusion to the non-dependent 
kidney was 37–39%.18 This represents an increase in per-
fusion to the dependent kidney of approximately 50% and 
suggests a potential mechanism through which sleep 
posture may influence the development of renal calculi.
7.  Potential Vascular Etiology of Urinary 
Stone Disease
Given that urinary stone disease is potentially related to 
differential perfusion, the renal vasculature must be con-
sidered. Blood flow to the deepest portions of the renal 
medulla is mediated by the vasa recta that travels par-
allel to and in close contact with the collecting ducts. 
These vessels are very delicate and travel through an en-
vironment that is characterized by increased osmolality, 
decreased oxygenation, and the transition between lami-
nar and turbulent flow at points where the vasa recta 
branch into plexuses before returning toward the renal 
cortex.19 These factors present a hostile environment and 
may predispose the vasa recta to injury. Furthermore, 
just as hypertension can accelerate atherosclerotic calci-
fication of arteries, hyperfiltration injury to the vasa 
recta may result in calcification of these delicate blood 
vessels. Some urinary stone diseases might then be the 
result of erosion of these calcifications into the nearby 
collecting ducts.
8.  Cardiovascular Management of Urinary 
Stone Disease
The fact that urinary stone disease has now been so con-
vincingly associated with both cardiovascular risk factors 
and cardiovascular disease places our current medical 
stone management regimens in a different perspective. 
General recommendations for the prevention of recurrent 
urinary stone disease have included increased fluid intake, 
decreased sodium intake, decreased animal protein intake, 
and decreased oxalate-rich food intake. More specific rec-
ommendations tailored to the results of 24-hour urine 
metabolic studies have also included the use of alka-
linizing agents and antihypertensive thiazide diuretics. 
Interestingly, recommendations for decreased sodium 
intake, decreased animal protein intake, and the use of 
antihypertensive thiazide diuretics are also employed 
in standard cardiovascular risk reduction strategies. In-
deed, one recent study of the HPFS, NHS I and NHS II 
demonstrated that the Dietary Approaches to Stop Hy-
pertension diet involving high fruit and vegetable intake, 
moderate low-fat dairy intake, and low sodium and ani-
mal protein intake decreases the incidence of urinary 
stone disease by approximately 40%.20 This finding sug-
gests the intriguing possibility that urinary stone disease 
may be appropriately considered as a sequela of cardio-
vascular disease and should potentially be treated as such, 
rather than as merely a disorder of mineral metabolism.
9.  Genetic Basis of Urinary Stone Disease
Although urinary stone disease is generally considered a 
sporadic disease, familial tendencies have been observed. 
Using the Vietnam Era Twin Registry of 3,391 male–male 
twins serving in the United States military, the concor-
dance rates for stone disease were 32% for monozygotic 
twins and 17% for dizygotic twins leading to a heritabil-
ity calculation of 56%.21 In Danish twin databases involv-
ing 9,061 male and female same-sex twins, urinary stone 
concordance rates were 24% for monozygotic twins and 
9% for dizygotic twins (M.L.S. et al., unpublished data, 
2010). The large differences in concordance rates between 
monozygotic and dizygotic twins in these studies sug-
gest a high level of genetic influence. In accordance with 
the suspected genetic basis for urinary stone disease, 
multiple gene targets have been evaluated, ranging from 
the vitamin D receptor gene to genes involved in the func-
tion of various ion transport channels.22 While no single 
gene appears to be solely responsible for the develop-
ment of urinary stone disease in humans, alterations of 
these genes may be part of the multifactorial process 
leading to conditions favorable for stone formation.
10. Conclusion
Urinary stone disease is now being increasingly linked to 
cardiovascular risk factors and diseases. Whether one dis-
ease predisposes a patient to the other or whether some-
thing else entirely predisposes patients to both diseases 
is a matter for further study. Nevertheless, it is possible 
that vascular diseases may play a role in the formation 
of urinary calcifications. Regardless, risk reduction strat-
egies for both diseases overlap significantly and raise the 
possibility that urinary stone disease should be appro-
priately classified and treated as one of the manifestations 
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of cardiovascular disease. Through such an approach, a 
better understanding of urinary stone disease may result, 
allowing for the development of improved stone proph-
ylaxis strategies.
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